China Based Wuxi Biologics, A Global Company With Leading Open-Access Biologics Technology Platforms, Announced That It Has Signed A 10-Year Lease For A Clinical Manufacturing Facility (Mfg18) In Cranbury, New Jersey.The New Clinical Manufacturing Facility Will Install Total 6000 L Bioreactors, Process Development (Pd), Quality Control (Qc) Labs, Along With Supporting Functions. The 66,000-Square-Foot Facility Is Expected To Become Operational In Late 2020 And Will Bring In Up To 100 Jobs To The Region.This News Follows Wuxi Biologics' Recent Purchase Of Land To Build A New 107,000-Square-Foot Clinical And Commercial Manufacturing Facility In Worcester, Massachusetts, And The Lease Of A 33,000-Square-Foot Site To Establish A Process Development Lab In King Of Prussia, Pennsylvania."We Are Excited To Announce Our Third Site In The United States And Proud To Become A Member Of The New Jersey Community. Cranbury Is A Growing Hub For The Biotech And Biopharma Industries, And We Look Forward To Working With And Serving Our Partners In The Area To Benefit Patients Worldwide," Said Dr. Chris Chen, Ceo Of Wuxi Biologics.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!